SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Nov 29, 2016

Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Nov. 29, 2016 · CIK: 0001503802 · Accession: 0001193125-16-779466

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-214489

Date
November 29, 2016
Author
Christopher B. Primiano
Form
CORRESP
Company
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)

Letter

KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE, SECOND FLOOR

NEWTON, MA 02459

November 29, 2016

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Karyopharm Therapeutics Inc.

Registration Statement on Form S-3

File No. 333-214489

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-214489) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on December 1, 2016, or as soon thereafter as practicable.

Very truly yours,
Karyopharm Therapeutics Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 KARYOPHARM THERAPEUTICS INC.

 85 WELLS AVENUE, SECOND FLOOR

 NEWTON, MA 02459

November 29, 2016

 Via EDGAR

Securities and Exchange Commission

 Division of Corporation
Finance

 100 F Street, N.E.

 Washington, D.C. 20549

Re:
Karyopharm Therapeutics Inc.

 Registration Statement on Form S-3

File No. 333-214489

 Request
for Acceleration

 Ladies and Gentlemen:

 Pursuant to
Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File
No. 333-214489) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on December 1, 2016, or as soon thereafter as practicable.

Very truly yours,

Karyopharm Therapeutics Inc.

 By:

/s/ Christopher B. Primiano

 Name:

Christopher B. Primiano

 Title:

Senior Vice President, Corporate Development,

General Counsel and Secretary